Clinical usefulness of positron emission tomography in prostate cancer;Utilité clinique de la tomographie par émission de positons dans le cancer de la prostate

Presse Medicale

Volumn 36, Issue 12 II, 2007, Pages 1794-1806

  Talbot, Jean Noël ^a   Gutman, Fabrice ^a   Huchet, Virginie ^a   Kerrou, Khaldoun ^a   Balogova, Sona ^a   Kerrouche, Nacer ^a   Montravers, Françoise ^a   Grahek, Dany ^a   Cussenot, Olivier ^b   Gattegno, Bernard ^b   Thibault, Philippe ^b  

^a Service de medecine nucleaire   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROMETHYLCHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUOROMETHYLCHOLINE;

CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; SHORT SURVEY; BONE TUMOR; MALE; PATHOLOGY; PROSTATE TUMOR; REVIEW; SCINTISCANNING; TUMOR RECURRENCE;

BONE NEOPLASMS; CHOLINE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 36249011474     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.02.030     Document Type: Short Survey

References (54)

1. Effert P.J., Bares R., Handt S., Wolff J.M., Bull U., and Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 (1996) 994-998
2. Liu I.J., Zafar M.B., Lai Y.H., Segall G.M., and Terris M.K. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 (2001) 108-111
3. Oyama N., Akino H., Suzuki Y., Kanamaru H., Miwa Y., Tsuka H., et al. Prognostic valueof 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 4 (2002) 99-104
4. Agus D.B., Golde D.W., Sgouros G., Ballangrud A., Cordon-Cardo C., and Scher H.I. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 58 (1998) 3009-3014
5. Danella J.F., deKernion J.B., Smith R.B., and Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 149 (1993) 1488-1491
6. Gervasi L.A., Mata J., Easley J.D., Wilbanks J.H., Seale-Hawkins C., Carlton Jr. C.E., et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142 (1989) 332-336
7. Hricak H., Dooms G.C., Jeffrey R.B., Avallone A., Jacobs D., Benton W.K., et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162 (1987) 331-336
8. Platt J.F., Bree R.L., and Schwab R.E. The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol 149 (1987) 315-318
9. Sonnad S.S., Langlotz C.P., and Schwartz J.S. Accuracy of MR imaging for staging prostate cancer: a meta-analysis to examine the effect of technologic change. Acad Radiol 8 (2001) 149-157
10. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
11. Sanz G., Robles J.E., Gimenez M., Arocena J., Sanchez D., Rodriguez-Rubio F., et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84 (1999) 1028-1031
12. Heicappell R., Muller-Mattheis V., Reinhardt M., Vosberg H., Gerharz C.D., Muller-Gartner H., et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36 (1999) 582-587
13. Yeh S.D., Imbriaco M., Larson S.M., Garza D., Zhang J.J., Kalaigian H., et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23 (1996) 693-697
14. Shreve P.D., Grossman H.B., Gross M.D., and Wahl R.L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199 (1996) 751-756
15. Morris M.J., Akhurst T., Osman I., Nunez R., Macapinlac H., Siedlecki K., et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59 (2002) 913-918
16. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., and Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
17. Fowler Jr. J.E., Brooks J., Pandey P., and Seaver L.E. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 153 (1995) 1011-1014
18. Van der Kooy M.J., Pisansky T.M., Cha S.S., and Blute M.L. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 49 (1997) 65-70
19. Rogers R., Grossfeld G.D., Roach III M., Shinohara K., Presti Jr. J.C., and Carroll P.R. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol 160 (1998) 1748-1753
20. Seltzer M.A., Barbaric Z., Belldegrun A., Naitoh J., Dorey F., Phelps M.E., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162 (1999) 1322-1328
21. Schöder H., Herrmann K., Gonen M., Hricak H., Eberhard S., Scardino P., et al. 2-[18F]-fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with rising prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11 (2005) 4761-4769
22. Oyama N., Akino H., Suzuki Y., Kanamaru H., Sadato N., Yonekura Y., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29 (1999) 623-629
23. Hawkins R.A., Choi Y., Huang S.C., Hoh C.K., Dahlbom M., Schiepers C., et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 33 (1992) 633-642
24. Blake G.M., Park-Holohan S.J., Cook G.J., and Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 31 (2001) 28-49
25. Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28 (2001) 117-122
26. Kato T., Tsukamoto E., Kuge Y., Takei T., Shiga T., Shinoara N., et al. Accumulation of [11C]-acetate in normal prostate and benign hyperplasia : comparison with prostate cancer. Eur J Nucl Med Mol Imaging 29 (2002) 1492-1495
27. Oyama N., Akino H., Kanamaru H., Suzuki Y., Muramoto S., Yonekura Y., et al. 11C acetate PET imaging of prostate cancer. J Nucl Med 43 (2002) 181-186
28. Fricke E., Machtens S., Hofmann M., van den Hoff J., Bergh S., Brunkhorst T., et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 (2003) 607-611
29. Oyama N., Miller T.R., Dehdashti F., Siegel B.A., Fischer K.C., Michalski J.M., et al. 11C acetate PET imaging of prostate cancer : detection of recurrent disease at PSA relapse. J Nucl Med 44 (2003) 549-555
30. Wachter S., Tomek S., Kurtaran A., Wachter-Gerstner N., Djavan B., Becherher A., et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 24 (2006) 2513-2519
31. Ackerstaff E., Pflug B.R., Nelson J.B., and Bhujwalla Z.M. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61 (2001) 3599-3603
32. Swanson M.G., Vigneron D.B., Tabatabai Z.L., Males R.G., Schmitt L., Carroll P.R., et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSItargeted postsurgical prostate tissues. Magn Reson Med 50 (2003) 944-954
33. Kotzerke J., Volkmer B.G., Glatting G., van den Hoff J., Gschwend J.E., Messer P., et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42 (2003) 25-30
34. Sutinen E., Nurmi M., Roivainen A., Varpula M., Tolvanen T., Lehikoinen P., et al. Kinetics of [11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 31 (2004) 317-324
35. Scher B., Seitz M., Albinger W., Tiling R., Scherr M., Becker H.C., et al. Value of 11C choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34 (2007) 45-53
36. Reske S.N., Blumstein N.M., Neumaier B., Gottfried H.W., Finsterbusch F., Kocot D., et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47 (2006) 1249-1254
37. Matorana G., Schiavinia R., Corti B., Farsad M., Salizzzoni E., Brunocilla E., et al. 11C choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176 (2006) 954-960
38. Yamaguchi T., Lee J., Uemura H., Sasaki T., Takashashi N., Oka T., et al. Prostate cancer : a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32 (2005) 742-748
39. Farsad M., Schiavina R., Castellucci P., Nanni C., Corti B., Martorana G., et al. Detection and localization of prostate cancer : correlation of 11C-choline PET/CT with histopathologic step-section an analysis. J Nucl Med 46 (2005) 1642-1649
40. de Jong I.J., Pruim J., Elsinga P.H., Vaalburg W., and Mensink H.J. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44 (2003) 331-335
41. Picchio M., Messa C., Landoni C., Gianolli L., Sironi S., Brioschi M., et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169 (2003) 1337-1340
42. De Jong J.J., Pruim J., Elsinga P.H., Vaalburg W., and Mensink H.J.A. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44 (2003) 32-39
43. De Grado T.R., Coleman R.E., Wang S., Baldwin S.W., Orr M.D., Robertson C.N., et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61 (2001) 110-117
44. De Grado T.R., Reiman R.E., Price D.T., Wang S., and Coleman R.E. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43 (2002) 92-96
45. Price D.T., Coleman R., Lino R., Robertson C., Polascik T., and De Grado T.R. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron tomography of androgen dependent and androgen independent prostate cancer. J Urol 168 (2002) 273-280
46. Kwee S.A., Coel M.N., Lim J., and Ko J.P. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 173 (2005) 252-255
47. Schmid D.T., John H., Zweifel R., Cservenyak T., Westera G., Goerres G.W., et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235 (2005) 623-628
48. Kwee S.A., Wei H., Sesterhenn I., Yun D., and Coel M.L. Localization of primary prostate cancer with dual-phase 18F-Fluorocholine PET. J Nucl Med 47 (2006) 262-269
49. Gutman F., Thomassin J., Kerrou K., Grahek D., Montravers F., and Talbot J.N. L'intérêt de la TEP/TDM à la fluorocholine-(18F) illustré par l'exemple. Méd Nucl. 30 (2006) 391-398
50. Langsteger W., Heinisch M., and Fogelman I. The role of fluorodeoxyglucose, 18Fdihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36 (2006) 73-92
51. Hacker A., Jeschke S., Leeb K., Prammer K., Ziegerhofer J., Sega W., et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer : comparison of [18F] fluorocholine positron emission tomography - computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176 (2006) 2014-2018
52. Heinisch M., Dirisamer A., Loidl W., Stoiber F., Gruy B., Haim S., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. Mol Imaging Biol 8 (2006) 43-48
53. Gutman F., Aflalo-Hazan V., Kerrou K., Montravers F., Grahek D., and Talbot J.N. 18Fcholine PET/CT for initial staging of advanced prostate cancer. AJR Am J Roentgenol 187 (2006) W618-W621
54. Cimitan M., Bortolus R., Morassut S., Canzonieri V., Garbeglio A., Baresic T., et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33 (2006) 1387-1398